reports
argenx to Report First Quarter 2025 Financial Results and Business Upd...
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025 May 1, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 8, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 2025 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at . A replay of th...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Thomas Vranken
argenx FIRST LOOK: Positive CHMP opinion for CIDP
argenx received a positive opinion from the CHMP of the EMA for Vyvgart in treating CIDP in adults with progressive or relapsing disease after prior treatment with corticosteroids or immunoglobulins. The European Commission will now decide on the regulatory submission within 60 days. Vyvgart is the first novel CIDP treatment in over 30 years and could potentially be self-administered. This approval is expected to lead to significant sales in the EU, with EU peak sales estimated at $1.1bn (KBCSe...
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa)...
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDPFirst novel mechanism of action for CIDP treatment in more than 30 yearsCHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial European Commission (EC) decision on marketing authorization application (MAA) expected within approximately two months April 28, 2025, 07:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Lynn Hautekeete
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Wim Hoste
Umicore FIRST LOOK: 1Q qualitative trading update, FY25 guidance reite...
Umicore issued an unexpected (qualitative) trading update in which it also reiterated its FY25 adjusted EBITDA guidance range of € 720-780m. Given the uncertain economic outlook, we decided to lower our forecast by 3% to € 734m, closer to the bottom end of the guidance range. We remind that Umicore recently organized a CMD, expressing the ambition to try to monetize past investments in Battery Materials, acknowledging that some additional capex and equity investment into the Ionway JV are still ...
Rectification to announcement Resolutions Annual General Meeting of Sh...
Rectification to announcement Resolutions Annual General Meeting of Shareholders of ForFarmers N.V. Lochem, 17 April 2025 Rectification to announcement Resolutions Annual General Meeting of Shareholders of ForFarmers N.V. Unfortunately there is an error in the press release published earlier today entitled ‘Resolutions Annual General Meeting of Shareholders of ForFarmers N.V.’. Under the heading ‘Share buy-back programme for (depositary receipts for) shares related to remuneration plans and employee participation plans’, the press release states that the share buy-back programme running ...
Rectificatie op het bericht Besluiten Algemene Vergadering van Aandeel...
Rectificatie op het bericht Besluiten Algemene Vergadering van Aandeelhouders ForFarmers N.V. Lochem, 17 april 2025 Rectificatie op het bericht Besluiten Algemene Vergadering van Aandeelhouders ForFarmers N.V. Per abuis staat er in het vandaag gepubliceerde persbericht met de titel ‘Besluiten Algemene Vergadering van Aandeelhouders ForFarmers N.V.’ een fout. In het bericht staat vermeld onder de paragraaf ‘Inkoopprogramma eigen aandelen ten behoeve van (certificaten van) aandelen-gerelateerde beloningsplannen en medewerkersparticipatieplannen’ dat het inkoopprogramma van eigen aandelen ...
Besluiten Algemene Vergadering van Aandeelhouders ForFarmers N.V.
Besluiten Algemene Vergadering van Aandeelhouders ForFarmers N.V. Lochem, 17 april 2025 Besluiten Algemene Vergadering van Aandeelhouders ForFarmers N.V. Tijdens de Algemene Vergadering van Aandeelhouders van ForFarmers N.V. (hierna respectievelijk: de ‘Algemene Vergadering’ en ‘ForFarmers’), die vandaag is gehouden, hebben de aandeelhouders de jaarrekening over het boekjaar 2024 vastgesteld en tevens het dividendvoorstel over genoemd boekjaar goedgekeurd. Het dividend van € 0,20 per gewoon aandeel zal geheel in contanten, onder inhouding van 15% dividendbelasting, aan de aandeelho...
Resolutions General Meeting of Shareholders ForFarmers N.V.
Resolutions General Meeting of Shareholders ForFarmers N.V. Lochem, 17 April 2025 Resolutions General Meeting of Shareholders ForFarmers N.V. During the General Meeting of Shareholders of ForFarmers N.V. (hereinafter referred to as the 'General Meeting' and 'ForFarmers' respectively), held today, the shareholders adopted the financial statements for the 2024 financial year and also approved the dividend proposal for the said financial year. The dividend of € 0,20 per ordinary share will be paid to ForFarmers' shareholders entirely in cash, after deducting 15% dividend withholding tax...
Umicore S.A.: 1 director
A director at Umicore S.A. bought 14,000 shares at 7.700EUR and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
argenx Announces Annual General Meeting of Shareholders on May 27, 202...
argenx Announces Annual General Meeting of Shareholders on May 27, 2025 April 11, 2025, 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 27, 2025 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the Annual General Meet...
- Thomas Vranken
argenx FDA approves Vyvgart Hytrulo as pre-filled syringe for MG and C...
argenx obtained FDA approval for a PFS presentation of Vyvgart Hytrulo for self-injection for patients with AChR+ gMG or CIDP. The 20-30 second injection can now be administered by patients themselves after proper instruction, freeing them to receive treatment in healthcare settings, at home or on the go. With no specific monitoring or training requirements, the label provides a lot of flexibility for patients. We see the approval as the next phase in maintaining Vyvgart's launch momentum as it ...
- Hilde Van Boxstael
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Lewi
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for...
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringeSelf-injection provides gMG and CIDP patients with flexibility for when and where to receive treatment – at home, while ‘on the go’ or in a healthcare setting Approval reflects commitment to innovating the patient experience with individualized, safe and effective therapies April 10, 2025...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
US Tariffs Navigating the impact on Benelux equities
Trumps reciprocal tariffs caused a massive blow to equity markets, following a pressured period of escalating trade wars. Retaliatory measures can further heavily damage market confidence, as seen Friday when China announced their 34% tarrif of US goods. International trade policies have never moved this erratic and untransparant, with uncertainty and volatility being the baseline for now. In this report we highlight the key stocks in our coverage relevant to this discussion.
EURN EURONAV NV
ABN ABN AMRO BANK NV DEPOSITARY RECEIPTS
FAGR FAGRON SA
EVS EVS BROADCAST EQUIPMENT SA
XIOR XIOR STUDENT HOUSING N.V.
SOLB SOLVAY SA
UCB UCB S.A.
COFB COFINIMMO SA
DIE D'IETEREN SA
AGFB AGFA-GEVAERT NV
IBAB ION BEAM APPLICATIONS SA
AALB AALBERTS N.V.
ONTEX ONTEX GROUP N.V.
MELE MELEXIS NV
CSM CORBION NV
ABI ANHEUSER-BUSCH INBEV SA/NV
EXO EXOR N.V.
ASML ASML HOLDING NV
ARGX ARGEN-X SE
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
ADYEN ADYEN NV
AUTL AUTOLUS THERAPEUTICS ADS
BAR BARCO NV
DEME DEME GROUP NV
FLOW FLOW TRADERS LTD
SYENS SYENSQO
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Thomas Vranken
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sus...
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients ADHERE+ oral presentation features long-term CIDP data demonstrating VYVGART Hytrulo’s durable efficacy, sustained functional improvements and favorable safety profileargenx continues to advance a robust neuromuscular pipeline of clinical candidates; first-in-human data of ARG...
- Hilde Van Boxstael
- Thomas Couvreur
- Wim Hoste
- Wim Hoste
Umicore Will the real cash flow generator please stand up?
Last week's long awaited strategy update highlighted Umicore's ambition to try to monetize past investments in Battery Materials, acknowledging that some additional capex and equity investment into the Ionway JV are still necessary to achieve this. In the meantime, the company will actively explore partnerships in Battery Materials. The financial targets for Battery Materials were above our expectations and the same can be said for the foundation businesses, particularly Catalysis, which is to b...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.